Genmab — Marts 2020
-
-
I hope we don't get delays to epcotitamab. We need to catch up with Roche!
-
JNJ does, and they named 2 new JNJ babies with, as usual, some very easy names... JNJ-64407564 Talquetamab and JNJ-64007957 Teclistamab https://clinicaltrials.gov/ct2/history/NCT04108195?A=5&B=6&C=merged#StudyPageTop
-
Det er desværre nok ret sandsynligt at epcotitamab bliver fanget i alt det her og at nye studier derfor bliver forsinket
-
Mange allerede aktive studier bliver jo også forsinket fordi indrullering går kraftigt ned i hastighed. Og at det kan blive svært for nogle patienter der allerede er indrulleret at få de nødvendige follow up
-
Hvis Roche bliver tilsvarende forsinket, så er det ikke så slemt
-
Det kommer lidt an på hvorhenne man er i cyklus. Hvis studie er færdi og man blot skal fortage dataanalyse (tager 2-4 mdr) og efterfølgende igang med at designe nye studier, så bliver man ikke ret meget ramt. Men hvis man stort set er færdig med at designe et studie og skal til at i gang så bliver man ramt
-
Sylke Maas (BioNTech):
That is the DuoBody, we are - you refer to PD-L1 4-1BB DuoBody which we are developing in cooperation with our partner Genmab. We are pretty advanced in our dose escalation. So have cleared a number of dose levels which were planned and the data disclosure presentation would definitely include data, referring to safety of different doses, probably also the Phase II dose.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind